Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 245

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors

Open access
Abdul Razak, Albiruni R., Mau-Soerensen, Morten, Gabrail, Nashat Y., Gerecitano, John F., Shields, Anthony F., Unger, Thaddeus J., Saint-Martin, Jean R., Carlson, Robert, Landesman, Yosef, McCauley, Dilara, Rashal, Tami, Lassen, Ulrik, Kim, Richard, Stayner, Lee-Anne, Mirza, Mansoor R., Kauffman, Michael, Shacham, Sharon, Mahipal, Amit·2016·Journal of Clinical Oncology

Abstract

Purpose: This trial evaluated the safety, pharmacokinetics, pharmacodynamics, and efficacy of selinexor (KPT-330), a novel, oral small-molecule inhibitor of exportin 1 (XPO1/CRM1), and determined the recommended phase II dose. Patients and Methods: In total, 189 patients with advanced solid tumors received selinexor (3 to 85 mg/m 2) in 21- or 28-day cycles. Pre- and post-treatment levels of XPO1 mRNA in patient-derived leukocytes were determined by reverse transcriptase quantitative polymerase chain reaction, and tumor biopsies were examined by immunohistochemistry for changes in markers consistent with XPO1 inhibition. Antitumor response was assessed according Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 guidelines. Results: The most common treatment-related adverse events included fatigue (70%), nausea (70%), anorexia (66%), and vomiting (49%), which were generally grade 1 or 2. Most commonly reported grade 3 or 4 toxicities were thrombocytopenia (16%), fatigue (15%), and hyponatremia (13%). Clinically significant major organ or cumulative toxicities were rare. The maximum-tolerated dose was defined at 65 mg/m 2 using a twice-a-week (days 1 and 3) dosing schedule. The recommended phase II dose of 35 mg/m 2 given twice a week was chosen based on better patient tolerability and no demonstrable improvement in radiologic response or disease stabilization compared with higher doses. Pharmacokinetics were dose proportional, with no evidence of drug accumulation. Dose-dependent elevations in XPO1 mRNA in leukocytes were demonstrated up to a dose level of 28 mg/m 2 before plateauing, and paired tumor biopsies showed nuclear accumulation of key tumor-suppressor proteins, reduction of cell proliferation, and induction of apoptosis. Among 157 patients evaluable for response, one complete and six partial responses were observed (n = 7, 4%), with 27 patients (17%) achieving stable disease for ≥ 4 months. Conclusion: Selinexor is a novel and safe therapeutic with broad antitumor activity. Further interrogation into this class of therapy is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2015.65.3949

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 245

Metadata

Authors
Abdul Razak, A. R., Mau-Soerensen, M., Gabrail, N. Y., Gerecitano, J. F., Shields, A. F., Unger, T. J., Saint-Martin, J. R., Carlson, R., Landesman, Y., McCauley, D., Rashal, T., Lassen, U., Kim, R., Stayner, L.-A., Mirza, M. R., Kauffman, M., Shacham, S., & Mahipal, A.
Venue
Journal of Clinical Oncology
Published
2016-12-01
Volume
34
Issue
34
Pages
4142-4150
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2290633618
Cited by
245
References
1
FWCI
12.94
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. https://app.cochat.ai/papers/10.1200/jco.2015.65.3949
The paper
Abdul Razak, A. R., Mau-Soerensen, M., Gabrail, N. Y., Gerecitano, J. F., Shields, A. F., Unger, T. J., Saint-Martin, J. R., Carlson, R., Landesman, Y., McCauley, D., Rashal, T., Lassen, U., Kim, R., Stayner, L.-A., Mirza, M. R., Kauffman, M., Shacham, S., & Mahipal, A. (2016). First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2015.65.3949

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.